How to measure glycemic instability?;Comment quantifier l'instabilite glycemique?

Diabetes and Metabolism

Volumn 26, Issue 2, 2000, Pages 148-151

  Selam, J L ^a  

^a HÔTEL DIEU   (France)

Author keywords

Brittle diabetes; Glycemic instability; Glycemic reproducibility; Home blood glucose monitoring; Hypoglycemia

Indexed keywords

ARTICLE; BLOOD GLUCOSE MONITORING; HOME MONITORING; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MEASUREMENT; REPRODUCIBILITY; STANDARD; BLOOD; EVALUATION; GLUCOSE BLOOD LEVEL; METABOLISM; METHODOLOGY;

BLOOD GLUCOSE; BLOOD GLUCOSE SELF-MONITORING; DIABETES MELLITUS, TYPE 1; EVALUATION STUDIES; HUMANS; REPRODUCIBILITY OF RESULTS;

EID: 0034169585     PISSN: 03381684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Service FJ, Nelson L. Characteristics of glycemic stability. Diabetes Care, 1980, 3, 58-62.
2. Service FJ, Molnar GD, Rosevear JW, Ackerman E, Gatewood LC, Taylor WF. Mean amplitude of glycemic excursions, a measure of diabetic instability. Diabetes, 1970, 19, 644-555.
3. Tattersall R. Brittle diabetes. Clin Endocr Metab, 1977, 6, 3, 403-419.
4. Kent LA, Gill GV, William G. Mortality and outcome of patients with brittle diabetes and recurrent ketoacidosis. Lancet, 1994, 344, 778-781.
5. Schade DS, Burge MR, Hardy KJ. Brittle diabetes : an update. Clinical Diabetes, 1992, 83-86.
6. Tattersall R, Gregory R, Selby C, Kerr D, Heller S. Course of brittle diabetes : a 12 year follow-up. Brit Med J, 1991, 302, 1240-1243.
7. Gill GV, Lucas S, Kent LA. Prevalence and characteristics of brittle diabetes in Britain. QJM, 1996, 89, 839-843.
8. The Diabetes Control and Complications Trial Research Group. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes, 1995, 44, 968-983.
9. Selam JL. Réévaluation du risque hypoglycémique au cours de l'insulinothérapie intensive. In Journées de Diabétologie Flammation Médecine-Sciences 1998, 258-280.
10. Holleman F, Hoekstra JBL. Insulin lispro. N Engl J Med, 1997, 337, 175-183.
11. Haardt MJ, Selam JL, Bethoux JP, Dorange C, Mace B et al. A cost-benefit comparison of intensive diabetes management with implantable pumps versus multiple subcutaneous injections with type 1 diabetes. Diabetes Care, 1994, 17, 847-851.
12. Jullien V, Elgrably F, Traynard PY, Slama G, Selam JL. Evaluation of a strutured 4-day educational programme for intensive insulin therapy. Diabet Med, 1997, 14, 894.
13. Hanaire-Boutin H, Broussolle C, Jeandidier N. Feasibility of intraperitoneal insulin therapy with programmable implantable pumps in IDDM. Diabetes Care, 1995, 18, 388-395.
14. Selam JL, Micossi Piero, Dunn FL Clinical trial of programmable implantable insulin pump for type 1 diabetes. Diabetes Care, 1992, 15, 877-857.
15. Service FJ, Peter PhD, O'Brien C, Rizza RA. Measurements of glucose control. Diabetes Care, 1987, 10, 225-237.
16. Kovatchev BP, Cox DJ, Gonder-Frederick LA, Clarke W. Symetrization of the blood glucose measurement scale and its applications. Diabetes Care, 1997, 20, 1655-1658.
17. Kovatchev BP, Cox DJ, Gonder-Frederick LA, Clarke W, Young-Hyman D, Schlundt D, Clarke W. Assessment of risk for severe hypoglycemia among adults with IDDM. Diabetes Care, 1998, 21, 1870-1875.
18. Molnar G.D. Taylor WF, Ho MM. Day-to-day variation of continuously monitored glycaemia : a further measure of diabetic instability. Diabetologia, 1972, 8, 342-348.